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Abstract
Pluripotency of cMyc genes may be one factor for the high glial cell differentiation in glioma thus it can 
become an alternative therapeutic target. The objective of the study is to analyze the cMyc mRNA expression 
and its relationship with the degrees of glioma malignancy. This is a cross-sectional study from 20 glioma 
samples with different degree of malignancy from Dr. Cipto Mangunkusumo General Hospital, Jakarta during 
the period of October 2014 until February 2015. The mRNA obtained from glioma samples are converted to 
cDNA and then amplified.  Relative quantification of cMyc mRNA expression is measured by calculating the 
cycle threshold values of Real Time RT PCR and normalized towards 18s rRNA to predict the relationship 
between the expression of cMyc and the degree of malignancy. The cMyc expression is increased in accordance 
with the tumor grade. The cMyc expressions in high grade glioma are 17424.23 folds higher when calibrated to 
the normal cell, whereas the genes in lower grade tumors are expressed with the rate of 6167.35. Although the 
values obtained are not statistically significant, this research has strengthened molecular diagnosis, specifically 
pluripotency as the factor that gives a greater prognostic relevance than the histopathologic diagnosis. As a 
conclusion, there is a clinical tendency where the relative mRNA expression was higher in in glioma cMyc high 
degrees compared with low-grade glioma, however it is not statistically significant.
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Ekspresi Relatif mRNA cMyc Sel Glioma Manusia
dan Hubungannya dengan Derajat Keganasan
Abstrak
Pluripotensi mRNA cMyc dapat menjadi salah satu faktor tingginya diferensiasi sel glial pada glioma 
sehingga dapat menjadi target terapi alternatif. Tujuan penelitian untuk menganalisa ekspresi mRNA cMyc 
dan dihubungkan dengan tingkat keganasan glioma. Penelitian dengan desain cross sectional dilakukan 
terhadap 20 sampel glioma dengan derajat keganasan berbeda yang berasal dari RSUPN Dr. Cipto 
Mangunkusumo selama Oktober 2014 sampai Februari 2015.  mRNA ditransformasi menjadi cDNA dan 
diamplifikasi menggunakan Accupower Two-Step RT-PCR with SYBR Green. Kuantifikasi relatif mRNA cMyc 
ditentukan dengan menghitung nilai cycle threshold pada RT PCR ang dinormalisasi dengan rRNA 18S untuk 
melihat hubungan antara ekspresi cMyc dan derajat keganasan glioma. Ekspresi cMyc ternyata lebih tinggi 
seiring dengan meningkatnya tingkat keganasan. Ekspresi cMyc pada glioma derajat tinggi senilai 17424,23 
kali lebih tinggi dibandingkan dengan ekspresi pada sel otak normal, sedangkan glioma derajat rendah 
mengalami ekspresi gen cMyc senilai 6167,30. Meskipun nilai yang diperoleh tidak signifikan secara statistik, 
penelitian ini telah menunjukkan bahwa diagnosis molekuler, terutama pluripotensi, dapat menjadi faktor 
penentu prognosis glioma selain ditentukan dengan derajat keganasan melalui pemeriksaan histopatologis. 
Terdapat kecenderungan secara klinis dimana ekspresi relatif  mRNA cMyc lebih tinggi pada glioma derajat 
tinggi dibandingkan dengan glioma derajat rendah, namun nilainya tidak signifikan secara statistik.  
Kata kunci: cMyc; glioma derajat tinggi; glioma derajat rendah.
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Introduction
Gliomas are primary brain tumors that develop 
from the glial cell. They are highly pluoripotent, 
thus may grow their own vasculature. With an 
incidence of 3–5 per 100.000 people in each year, it 
is considered to be the most common primary brain 
tumor. Despite it may occur in all ages, gliomas are 
most prevalent in adults over 45 years of age.1-3
According to WHO glioma may be differentiated 
into a low and high degree of invasion. Patients 
with highly invasive glioma are usually referred of 
having glioblastoma. Glioblastoma cases may be 
primary or secondary in term of etiology, by which 
primary glioblastoma occurs de novo whereas the 
secondary glioblastoma is originated from the low 
degrees glioma that developed into glioblastoma. 
Patients with this malignancy have the worst 
prognosis with high recurrence despite receiving 
conventional treatments. Such inconvenience is 
believed to be the result of the existence of cancers’ 
stem cells, which have such high capability of self 
renewal, pluripotency, and tumorigenicity.3
Treatments for this type of primary brain tumour 
have not been satisfying. Previous researchers 
have found that a group of glioma patients of 
similar degree of malignancy may respond 
differently to radiotherapy treatments.5 Some high 
grades glioma respond well to the treatments 
while others still show recurrences and resistance. 
Moreover numbers of them might have responded 
better than the lower grade glioma patients.  On 
the other hand the activity of transcription factors 
such the Sox2 and Nanog, which are the biological 
markers of pluripotency to stem cells, are found to 
be higher on the high grade glioma.6 These findings 
lead to the possibilities that there may have 
been another molecular biology factors causing 
the different behaviours of glioma, not merely its 
degree of malignancy based on histopathological 
studies. This research is conducted to analyze 
the correlation of c-Myc expression as another 
pluripotency marker towards the different degrees 
of glioma malignancy. 
Methods
This research used cross sectional study done 
in Biochemistry and Molecular Biology Laboratory, 
Faculty of Medicine Universitas Indonesia 
from October 2014 until February 2015, using 
subjects of 20 glioma patients from the Neurology 
Department of Dr. Cipto Mangunkusumo National 
Hospital, selected previously by the postgraduate 
researchers based on consecutive method which fit 
the criteria. A normal brain cell was used as control 
and was obtained from normal tissues of a glioma 
patient. Samples were derived from previously 
extracted brain cells that had been frozen down. 
The inclusion criteria were patients form Neurology 
Department of RSCM and other hospitals in Jakarta 
that were diagnosed with glioma of grade I-IV (WHO 
classifications) using histological examinations and 
had undergone tumour surgery. The exclusion 
criteria was the laboratory results from anatomical 
pathology did not show glioma according to WHO 
classifications (grade I-IV).  The degrees of glioma 
became the independent variable being measured, 
whereas the gene expression on PCR as the 
dependent one, with no confounding variable. 
This research had been approved by the Ethics 
Committee of the Faculty of Medicine Universitas 
Indonesia under an addendum of the research 
protocol of No. 207/H2.F1/ETIK/2014.
Analyzing Degree of Invasion 
To obtain the data, first we analyzed the degree 
of invasion determined by the histopathological 
features through hematoxylin and eosin (HE) 
staining.  According to the WHO classification 
glioma is differentiated into four grades. Grade I 
is the pilomyxoid astrocytoma (PMA), determined 
by the extrusive myxoid matrix and angiocentric 
arrangements of the tumor cells. Grade II gliomas 
are identified with diffused astrocytoma. Grade III is 
called the anaplastic (malignant) astrocytoma and 
lastly is the grade IV, which is called multiforme 
glioblastoma by which the infiltration is extensive.4 
RNA Isolation
The RNA was isolated using Geneaid kit, 
which was done by the postgraduate researcher. 
As much as 500 µL solution was added to 50-
100 mg glioma tissues to be homogenized. The 
cell homogenate was then stored at -80°C for 1 
month before performing RNA extraction or directly 
isolated. The first step of the isolation is adding 
100 µL chloroform to the cell homogenate, which 
was then mixed by shaking it back and forth for 
15 seconds and incubated for 2-15 minutes at 
room temperature. To separate the solution into 
3 phases centrifugation was done at 12.000g for 
15 minutes at 4°C to fulfill the protein isolation. 
As much as 250 µL isoproponal was added at the 
clear phase for RNA precipitations to occur. It was 
then mixed by shaking the tube in an upside-down 
manner and incubated for 5-10 minutes at room 
temperature. Afterwards another centrifugation 
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was done at 12.000g for 10 minutes at 4°C. RNA 
palette was washed with 75% ethanol, followed by 
another centrifugation of 7.500g for 5 minutes. The 
supernatants were disposed and the RNA pallete 
was left dry by leaving the microtest tube open. 
The RNA pallete was then re-suspended in 50 µL of 
nuclease free water and incubated at 55°-60°C for 
10-15 minutes. The RNA samples were then stored 
in a deep freezer - 80°C until further analysis.
cDNA Synthesis
The next step was to perform cDNA synthesis 
using AccuPower Cyclescript RT Premix (Bioneer®). 
As much as 1 µL of total RNA was added as the RNA 
template and 20 µL reaction volume was made with 
distilled water. The lyophilized transparent pellet was 
dissolved by vortexing and briefly spun down until 
dissolved completely. cDNA synthesis reaction was 
performed with single temperature reaction. The mix 
tube was placed in PCR machine programmed as 
37~55°C for 60 minutes and 95°C for 5 minutes. 
cDNA was then stored at -20°C until further analysis.
Analysis of c-Myc  Pluripotency
Finally the pluripotency of c-Myc was anlyzed 
by amplifying the cDNA using Accupower  Two- 
Step RT-PCR with SYBR Green (Bioneer®). 
The primers used for c-Myc were 5’-AGAAT-
GCTGTCCTCGCTGTT-3’ (forward primer) and 
5’-TTTCTTGCAGGCTTTGGTCT-3’ (reverse primer), 
whereas 18S rRNA primers (as internal control) were 
5’-AAACGGCTACCACATCCAAG-3’ (forward primer) 
and 5’-CCTCCAATGGATCCTCGTTA-3’ (reverse 
primer). For the experimental protocol, PCR (40 cy-
cles) was run for 10 minutes in 95oC; 30 seconds in 
59oC (for 18S primers) or in 57 oC (for cMyc primers), 30 
seconds under 72oC. Melting curve was then analyzed 
for 1 minute in 95oC temperature, 1 minute in 55oC and 
10 seconds at 55oC.
By using the RT PCR, the amount of amplification 
needed was used to determine  cMyc gene 
expressions quantitatively. The rRNA 18S gene was 
used as an external standard. The amplification of 
18S rRNA gene was done under a similar condition 
with cMyc. As a negative control the RNase free 
water was used to replace RNA in order to cross 
out any false positive results. The efficient value 
and cycle threshold (CT) was attained as a result 
of the RT PCR. The gene expression analysis was 
measured using the relative quantification hence 
the value of the relative mRNA concentration was 
retrieved using the Livak method.
Statistical Analysis
The parametric T-independent test analysis 
was used if the relative expression of each degree of 
malignancy normal using the log data transformation. 
The parametric measurement is used when there 
are two variables that are statistically independent. 
In this case, T-independent test may determine the 
statistical difference of relative expression of c-Myc 
gene on each degree of malignancy. 
Results
 The cMyc mRNA expression levels were 
examined from 20 human glioma with qPCR that 
has been normalized to 18S rRNA as a reference 
gene and calibrated with one normal human brain 
cell. Ten samples were classified as low grade 
glioma whereas the other 10 samples were high 
grade glioma. The PCR gives out cycle threshold 
(Ct) values for the mRNA within each sample 
and were used to determine the relative cMyc 
expression when calculated using Livak method. 
Beforehand the primers’ suitability and specificity 
has been confirmed by the one-peak presentation 
in melting curve analysis. The result I of Ct value is 
shown in Table 1, where there is a tendency that the 
relative expressions of cMyc mRNA in high grade 
glioma samples is higher than the expression rates 
in low grade glioma. However, certain samples of 
high degree malignancy presents with a lower rate 
than the average low degree malignancy. On the 
other hand the low grade glioma group shows a 
higher rate of expression when compared to the 
average high grade glioma but is still lower than the 
highest expression rate in high grade glioma group. 
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Table 1. Comparison of mRNA Expression of cMyc in Glioma Tumor  Tissue by qRT-PCR Analysis
High Degree Malignancy Low Degree Malignancy
Pathology Relative Expression Pathology
Relative 
Expression
Glioblastoma grade IV 10.06 Oligodendroglioma grade II 36232.58
Glioblastoma grade IV 7.16 Glioma grade II 14.37
Glioblastoma grade IV 137112.45 Oligoastrocytoma grade II 6.15
Glioblastoma grade IV 27.28 Xantroastrocytoma grade II       24833.5 
Astrocytoma grade III 586.10 Astrocytoma fibrillary grade II   564.18
Anaplastic astrocytoma grade III 18242.30 Oligoastrocytoma grade II 5.39
Astrocytoma grade III 18242.30 Astrocytoma fibrillary grade II 10.59
Astrocytoma fibrillary grade II 1.01 Ganglioma grade II 0.33
Glioblastoma grade III 10.23 Astrocytoma fibrillary grade II             1.8
Astrocytoma polycistic grade III 3.45 Astrocytoma fibrillary grade II 4.59
Figure 1 represents the ratio of cMyc mRNA 
for each degree of malignancy and the expressions 
in normal cell. It shows that there is a vast 
discrepancy between the rate of cMyc expression 
in high grade and lower grade glioma where there 
has been 17424.23 times of expression rate in the 
high degree malignancy and 6167.35 times in low 
degree malignancy. To obtain the best normality 
during statistical analysis the data is transformed 
with log transformation. When applied to the 
T-independent test analysis, the p value acquired 
is 0.613.
Figure 1. Relative Expression of cMyc mRNA (ratio) of the High Degree and Low   Degree 
Malignancy of Glioma towards the Expression in Normal Brain Cell 
Discussion
The mRNA expression level of cMyc were 
examined in 20 samples of  human glioma cells and 
1 sample of normal human brain cell with qPCR 
that has been normalized to 18S rRNA, a reference 
gene that resides in all cells and the expression 
is constant. In this experiment we only obtain 20 
samples for the total samples used instead of 20 
samples for each group because of the scarcity 
of glioma tissues available. Ten samples were 
classified as low grade glioma whereas the other 10 
samples were high grade glioma.  Moreover only 1 
sample of normal brain cell is obtained because it is 
almost statistically impossible to attain the sample 
in a large amount. Cobb’s11 research had only used 
5 samples of normal human brain cell as well in 
his research because not all glioma surgeries can 
invade the normal cells. 
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 The high grade glioma shows 17424.23 times 
of expression than in normal brain cells and the 
rate of the low grade glioma is 6167.35 times. This 
shows the rate of cMyc mRNA expression is in fact 
clinically higher in accordance to the degree of 
malignancy. A research conducted by Guo et al12 
also confirms that the mRNA oct4 expression, a 
gene with pluoripotent capability, on human glioma 
cell goes in accordance to its degree of malignancy 
where high grade tumor have tendencies to have 
a higher mRNA gene expressions. Hardiany et al13 
in Bicochemistry & Molecular Biology at Faculty of 
Medicine Universitas Indonesia confirms that there 
is a high expression of MnSOD mRNA on high 
grade glioma has been maintained by the hypoxic 
environment. This is due to the high Reactive 
oxidative species produced during this condition 
and makes it possible for its sensitivity towards 
oxygen-requiring radiotherapies to be reduced. 
 Not every sample represents similar pattern to the 
average value between the two groups. For instance 
certain low grade glioma sample, a WHO grade II 
oligodendroglioma with a rate expression 36232.58 
for one, has a higher rate cMyc mRNA expression 
than the relative expression of the high grade glioma 
but is still lower than the highest rate in the high 
degree malignancy. On the other hand, two samples 
of WHO grade III astrocytoma with a rate expression 
of 1.01 and 3.45 are relatively lower than the majority 
of the expressions in low grade glioma but are still 
higher than the lowest value in the low malignancy 
group. This versatile data may have contributed to 
the statistically insignificant result once applied to 
the T-independent test (p>0.05) despite the clinical 
tendency of a higher cMyc mRNA in accordance with 
degree of malignancy in this experiment. Among of the 
possible explanations of this variant and insignificant 
statistical result are the multiple pluripotent markers 
that influence differentiation of the tumor cells, an 
evidence for another better prognosis for the high 
degree malignancy, or merely an uneven distribution 
of malignancy within a tissue.
Pluripotency, the ability of genes as transcription 
factor to promote cell differentiation, may have been 
related greatly to the activity of cMyc expression. 
Because these genes have high ablilty to promote 
amplification of cancer cells, this might explain 
why certain low grade glioma has a higher rate of 
expression than the high grade glioma. There are 
several literatures suggest the high grade glioma, 
specifically WHO grade IV Glioblastoma, may 
be developed primarily or a result of a secondary 
development from the low grade glioma.4 The result 
where certain low glioma cells have a higher rate 
of expression may be explained by this principle, by 
which they may be have the potentials to develop 
into the higher grade glioma. However, further cohort 
research is needed to prove that assumption. 
Certain high grade glioma samples show lower 
rate of expression than the average rate on low 
grade glioma but are still higher than the lowest 
value in low degree malignancy. This may be an 
indicator that certain high grade gliomas might 
have good prognosis towards therapy. Aman et al5 
study on the variant responses of glioma patients 
towards radiotherapy had also proved likewise, 
where a few of the the high grade glioma patients 
gave better response towards therapy. Moreover, 
further cohort study is required to analyze the 
relationship between this pluripotency marker and 
radiotherapy response.
Conclusion
There is a clinical tendency where the c-Myc 
expression is higher in high degree glioma compared 
to low degree malignancy, however it is not statistically 
significant. Future research is recommended to 
conduct additional tests; pluripotency of transcription 
factors (Nanog, Sox 2, etc), hypoxia, and on cancer 
cells to determine another factors for the degree of 
malignancy of glioma other than histopathological 
method. Cohort study is needed to find the correlation 
between responds towards therapy and the survival 
rate of the patient. 
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